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Summary The occurrence of breast and thyroid multiple primary cancers was evaluated using data from the
Connecticut Tumor Registry. The study population consisted of 1618 women with primary thyroid cancer and
39,194 women with primary breast cancer diagnosed between 1935 and 1978. Thirty-four thyroid cancer
patients subsequently developed breast cancer and 24 breast cancer patients later had thyroid cancer. A
significantly elevated risk of thyroid cancer following breast cancer (SIR= 1.68) and breast cancer following
thyroid cancer (SIR= 1.89) was demonstrated. The finding was even more notable when compared with the
risks obtained for other sites. The elevated risk was particularly evident in women under 40 years of age at
time of diagnosis of the first cancer. Analysis by histologic type revealed that the highest risk of second
primary breast cancer was found among patients with follicular or mixed papillary-follicular thyroid cancer.
Women under age 40 with follicular carcinoma had a 10-fold risk ofdeveloping breast cancer (4 observed, 0.4
expected). An enhanced risk of second primary tumours was evident for the entire period after treatment of
the first primary, although it was highest within one year after diagnosis of the first primary. This may be due
to the close medical surveillance of cancer patients which would increase early diagnosis of second tumours.
Our findings suggest that breast and thyroid cancer may share common aetiologic features.
A relationship between thyroid disease and breast
cancer has been postulated for years. A geographic
correlation between incidence of goiter and breast
cancer has been noted (Bogardus & Finley, 1961;
Eskin, 1970), but a similar correlation between
thyroid cancer and breast cancer was not observed
(Waterhouse et al., 1976). Several studies have
demonstrated an increased risk of breast carcinoma
in patients with thyroid dysfunction (Repert, 1952;
Humphrey' & Swerdow, 1964) and thyroid cancer
(Chalstrey & Benjamin, 1966; Shands & Gatling,
1970), while others have shown either a slight, non-
significant excess (Schottenfeld & Berg, 1971;
Schoenberg, 1977) or none at all (Hedley et al.,
1981; Hoffman & McConahey, 1981). Thyroid
function in breast cancer patients has been
evaluated, also with contradictory results. Raised
serum TSH (thyroid stimulating hormone) levels
were observed in some studies (Mittra & Hayward,
1974; Rose & Davis, 1978), but others could not
confirm these findings (Adami et al., 1978;
MacFarlane et al., 1980). Recently there has been
controversy concerning the role of thyroxine
replacement therapy in the aetiology of breast
cancer (Kapdi & Wolfe, 1976; Shapiro et al., 1980).
Iodine deficiency has been suggested as an
aetiologic factor in follicular thyroid cancer
(Williams, 1979) and possibly breast cancer (Stadel,
1976). An ecologic correlation between alcohol
consumption and both thyroid and breast cancer
has also been noted (Breslow & Enstrom, 1974;
Williams, 1976), but not confirmed in another study
(Pochin, 1976). Schoenberg et al. (1973) proposed a
viral model for multiple primary malignancies
based on the observation that polyoma viruses
produced tumours of several sites in animals,
including the thyroid and breast.
To further explore the possible relationship
between thyroid cancer and breast cancer, we
analyzed data from the Connecticut Tumor
Registry to evaluate both the occurrence of thyroid
cancer following breast cancer and the reverse
tumour sequence, i.e. breast cancer subsequent to
thyroid cancer. The Connecticut Tumor Registry
offers an ideal opportunity to study this issue
because of the long follow-up, the large number of
patients, and the high percentage of histologically
confirmed cases.
Materials and methods
A series of 1618 women with primary thyroid
cancer and 39,194 with breast cancer diagnosed
between 1935 and 1978 were identified from the
Connecticut Tumor Registry. Excluded from the
analysis were 131 thyroid cancer patients (102
identified by death certificate or autopsy only; 24
not in active follow-up and 5 with simultaneous
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primaries), and 2652 breast cancer patients (2149
identified through death certificate or autopsy only;
227 patients for whom follow-up information was
not available and 276 with simultaneous primaries).
Simultaneous primaries were defined as occurring
within 2 months of diagnosis of the first primary.
Consequently, one case of simultaneous breast and
thyroid cancer was excluded. The final study
population consisted of 1487 and 36,542 primary
female thyroid and breast cancer patients,
respectively. Eighty-four percent of the thyroid
cancer patients and 93% of the breast cancer
patients (total=92%) were followed through 1978.
First primary diagnoses were histologically
confirmed for 98% of the thyroid cancer and 95%
of the breast cancer patients. Histologic
confirmation of the second cancer was only slightly
lower (96% for thyroid and 88% for breast).
Women-years at risk were calculated from date
of diagnosis of the first primary to date of
diagnosis of any second primary, date lost to
follow-up, date of death, or December 31, 1978,
whichever occurred first. Expected values were
derived from age, sex, calendar-year, and site-
specific Connecticut incidence rates (Monson,
1974). Ratios of observed to expected cancer cases
(SIR) and 95% Fisher exact confidence limits were
calculated assuming that the observed cases were
distributed as a Poisson variate (Rothman & Boice,
1979).
As cancer survival is fairly good for both thyroid
and breast cancer, an assessment of treatment was
indicated. In this study, evaluation of treatment
effects was limited, since only therapy received up
to 4 months post-diagnosis is routinely recorded in
the Connecticut Tumor Registry. Recording of
subsequent treatment is incomplete and was,
therefore, not included in this analysis. The major
types of treatment were surgery, radiation and
adjunct hormonal therapy. Hormonal treatment for
thyroid cancer primarily consisted of thyroxine
replacement therapy to suppress TSH levels. Since
thyroxine is generally prescribed for thyroid cancer,
it was therefore unexpected that only 8% of the
study patients were recorded as having received this
therapy. It is likely that for many cases, thyroxine
was not considered a "cancer directed therapy" and
therefore was not consistently coded. Hormonal
therapy for breast cancer included endocrine
(usually oophorectomy) and hormonal medications
(primarily oestrogens).
Breast cancer risk was analyzed by the various
thyroid cancer histologic types because they have
considerably differing survival rates and possibly
dissimilar aetiologies as well. Histologic types were
defined using the ICD-O (1976) morphology and
were grouped as: papillary, mixed papillary-
follicular, follicular, undifferentiated and medullary,
and unclassified.
Results
Table I presents descriptive characteristics of the
study population by tumour sequence and
treatment subgroups. Because of the incompleteness
of the hormone therapy data, it is not presented
separately. The majority of the patients received
surgical treatment and relatively few had radiation
therapy. Breast cancer following thyroid cancer was
by far the most frequent second primary site,
accounting for 35% (34/97) of the second tumours.
Thyroid cancer is a rare disease comprising <1%
(24/3147) of the second tumours in the breast
cancer series.
A significant excess of malignant tumours of the
thyroid following breast cancer (SIR= 1.68) and
breast cancer following thyroid cancer (SIR= 1.89)
Table I Descriptive characteristics of study cohort by tumour sequence and treatment
Tumour sequence
Thyroidfirst-.breast second Breastfirst--+thyroid second
Surgery Treatment group Surgery
Factor Total onlyb Radiationb TotaP onlyc Radiationc
No. women 1,487 1,115 281 36,542 23,786 10,353
Women years at risk (WYRS) 11,913 9,883 1,847 225,797 168,241 52,315
Mean age at first primary 47.3 43.5 56.0 58.4 58.4 55.9
Mean year at first primary 1964.7 1966.0 1960.3 1962.3 1962.1 1962.8
Mean WYRS 8.01 8.86 6.57 6.19 7.09 5.05
Total number second
primaries 97 75 21 3,147 2,274 810
aTreatment subgroups do not add up to total, because there are women with unknown treatment.
bIncludes treatment with thyroxine.
cIncludes treatment with post-menopausal hormones and endocrine surgery.BREAST AND THYROID CANCER 89
Table II Observed and expected multiple breast and thyroid cancers by tumour
sequence and treatment
Sequence series
Thyroidfirst-breast second Breastfirst---thyroid second
Observed Expecteda
Treatment (0) (E) OIE (95%CL) 0 Ea OIE (95%CL)
Total 34 17.99 1.89 24 14.27 1.68
1.31; 2.64 1.08; 2.50
Surgery only 26 14.59 1.78 19 10.78 1.76
1.16; 2.61 1.06; 2.75
Radiation 8 3.11 2.57 5 3.1 1.61
1.11; 5.07 0.52; 3.76
aExpected values do not add up to total due to exclusions for untreated and
unknown treatment.
was observed (Table II). The most striking
observation was a significantly increased risk in
both series among women under age 40 years at
diagnosis of the first primary (SIR: thyroid to
breast=2.91; breast to thyroid=4.37) (Figure 1). In
the breast to thyroid series, risk decreased with age
at first primary, so that by age 55 no excess risk
was seen. In the thyroid to breast series the elevated
risk was seen in all ages, except in the 50-59 year
group. An evaluation of absolute risk showed that
in the breast to thyroid series the risk was highest
in the under 40 group and decreased until there was
no excess at age 60+. In the thyroid to breast
series, the risk was elevated in each group, but was
highest in the under 40 and over 60 groups. The
high rate of multiple primary breast and thyroid
cancer in young women appears to be specific to
these two sites. Women less than 40 years old at
time of diagnosis of their first cancer comprised
41% of the 34 breast cancers following thyroid
cancer and 21% of the 24 thyroid cancers following
breast cancer. In contrast, only 29% of the other 63
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Figure 1 Risk of developing thyroid or breast cancer
by age at first primary and tumour sequence. (A)
breast to thyroid; (El) thyroid to breast. Lower 95%
confidence limit in parenthesis.
multiple primaries following thyroid cancer and 9%
of the other 3123 multiple primaries following
breast cancer occurred among women under age 40.
Patients treated solely with surgery had a
significant risk of developing breast cancer after
thyroid cancer (SIR= 1.78), and thyroid after breast
cancer (SIR= 1.76) (Table II). Patients receiving
radiation therapy (in all but one case as an adjunct
to surgery), also had an elevated but non-significant
risk (SIR: breast to thyroid series= 1.61), thyroid to
breast series=2.57). While it is known that the
group of 116 thyroid patients coded as being
treated with hormones does not include all of the
patients receiving hormonal therapy, it still should
be noted that they had a 5-fold risk of developing
breast cancer (Observed=4, Expected=0.72,
SIR=5.55; 95% confidence interval=1.51-14.22).
In the breast to thyroid series, no excess risk was
seen among the hormone treated patients.
Analysis by histologic type indicated that the
highest risk of breast cancer was found among
patients with follicular or mixed papillary and
follicular thyroid cancer (Table III). Again looking
at age, we found that women under age 40 with
follicular carcinoma exhibited approximately a 10-
fold risk of developing breast cancer. No significant
excess risk was observed in patients with papillary
carcinomas. An intermediate risk was noted in the
unclassified group as it was probably representative
of all histologic types. Among breast cancer
patients with thyroid cancer as a second primary,
3/5 (60%) women under 40 years of age had
cancers with a follicular component compared to
6/19 (31.6%) women over age 40. Although this
difference is not statistically significant, it is in the
direction of the finding for the reverse sequence.
Length of time between first and second primary
was examined in both series. Figure 2 illustrates
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Figure 2 Risk of developing thyroid or breast cancer
by time from diagnosis of first primary cancer to
diagnosis of second primary cancer and tumour
sequence. (A) breast to thyroid; (El) thyroid to breast.
Lower 95% confidence limit in parenthesis.
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that in the thyroid to breast series, the greatest risk
occurred within 10 years after the first primary and
thereafter declined. In the breast to thyroid series
no clear pattern was seen, but risk was still elevated
at 15 years after the first primary. Wofnen under 40
years of age had a particularly high risk in both
series within 5 years following diagnosis of the first
tumour. This pattern was not evident for the other
age groups.
An examination by year of diagnosis of first
primary revealed that in the thyroid to breast series
there was a continual rise in risk, with an SIR of
1.28 between 1935-49; 1.81 between 1950-59; 2.02
between 1960-69 and 2.30 between 1970-78. In the
breast to thyroid series, there was a similar trend
until 1970, when the excess risk decreased slightly.
(SIR: 1935-49=1.0; 1950-59=1.3; 1960-69=2.4;
1970-78=1.9). These patterns could be due to
improved early diagnosis and survivorship which
would put patients at risk of developing a second
primary.
Discussion
In our study, occurrence of breast and thyroid
multiple primaries was evaluated using data from
the Connecticut Tumor Registry. A significantly
elevated risk of thyroid cancer following breast
cancer and breast cancer following thyroid cancer
was demonstrated. This finding was even more
notable when compared to the risks obtained for
other sites. In the breast to thyroid series, the only
other second primary sites with a significant SIR
greater than 1.6 were contralateral breast cancer
and ovarian cancer. For thyroid as the initial
cancer, only kidney and pancreatic cancer had a
significant SIR over 1.8.
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The excess risk was particularly evident in
patients under age 40 at time of diagnosis of the
first cancer and among patients with follicular
carcinoma. An enhanced risk of second tumours
was evident for the entire period after diagnosis of
the first primary, although it was highest within one
year after diagnosis of the first primary. In patients
with breast cancer as the first primary a higher than
expected incidence of thyroid cancer was seen
mostly within one year after the diagnosis of breast
cancer. This may be due to the close medical
surveillance of cancer patients which would increase
the probability of early diagnosis of a second
primary cancer. For patients with thyroid cancer as
the first primary, excess risk was highest within the
first 10 years. It is not likely that the second
tumours occurring within the first year are due to
metastases, since the breast is not a usual site of
metastases for thyroid cancer (Heitz et al., 1976)
and tumours metastasizing to the thyroid gland are
rarely diagnosed as primaries (Meissner, 1978).
Previous studies have provided weak evidence for
a relationship between thyroid and breast cancer.
Schottenfeld & Berg, (1971), in their survey of
multiple primaries, observed a non-significant
increase of breast cancer following thyroid cancer.
A significant excess of thyroid cancer following
breast cancer was also reported, but the elevated
risk was similar in magnitude to the general excess
of second primaries. Schoenberg (1977) studied
second primaries recorded in the Connecticut
Tumor Registry between 1935-64 and noted no
increase on the incidence of thyroid cancer
following breast cancer (SIR=1.1) and an elevated
but non-significant risk of breast cancer among
patients with thyroid cancer (SIR= 1.8). Our study
includes Schoenberg's data but adds 14 years of
follow-up. The additional data now available
demonstrate that the risk of thyroid and breast
cancer occurring in either sequence in the same
person, is statistically significant.
The finding that young women (under age 40)
had the highest risk of developing either a second
primary thyroid or breast cancer, is suggestive of an
endocrine or genetic aetiology. Eight women were
diagnosed with a third primary in addition to the
breast and thyroid. Five of these 8 cases were 40
years of age or younger at the first primary. Four
had a malignancy of the contralateral breast and
one of the endometrium.
The high risk of breast cancer among women
with follicular thyroid cancer, especially women
under 40 years of age, suggests that histologic type
is an important variable to study. Since the mean
age of women with follicular cancer is somewhat
older than women with papillary or mixed
papillary-follicular type, it may be that young
women with follicular thyroid cancer constitute a
special subgroup with a different aetiology.
As previously mentioned, the data on treatment
were limited since they included only therapy given
within 4 months post-diagnosis of the first primary
and because thyroid hormone therapy was not
consistently coded. However, the short length of
time between diagnosis of the first and second
tumour is not consistent with a radiation effect.
Our findings suggests that breast and thyroid
cancer may share certain aetiologic features. For
instance, infertility has been associated with thyroid
dysfunction (Hembree & Vande Wiele, 1978) and
breast cancer (Cowan et al., 1981) and the
associated hormonal imbalance may be a factor in
the aetiology of both thyroid and breast cancer.
Apart from radiation exposure, no other risk
factors for thyroid cancer have been established
and known breast cancer risk factors could,
therefore, provide a direction for future studies of
thyroid cancer.
The authors would like to acknowledge the Connecticut
Cancer Epidemiology Unit, New Haven, Connecticut, for
providing us with Connecticut cancer incidence rates.
References
ADAMI, H.O., RIMSTEN, A., THOREN, L., VEGELIUS, J. &
WIDE, J. (1978). Thyroid disease and function in breast
cancer patients and non-hospitalized controls
evaluated by determination of TSH, T3, rT3 and T4
levels in serum. Acta. Chir. Scand., 144, 89.
BOGARDUS, G.M. & FINLEY, J.W. (1961). Breast cancer
and thyroid disease. Surgery, 49, 461.
BRESLOW, N.E. & ENSTROM, J.E. (1974). Geographic
correlations between cancer mortality rates and
alcohol-tobacco consumption in the United States. J.
Natl Cancer Inst., 53, 631.
CHALSTREY, L.J. & BENJAMIN, B. (1966). High incidence
of breast cancer in thyroid cancer patients. Br. J.
Cancer, 20, 670.
COWAN, L., GORDIS, L., TONASCIA, J.A. & SEEGAR
JONES, G. (1981). Breast cancer incidence in women
with a history of progesterone deficiency. Am. J.
Epidemiol., 114, 209.
ESKIN, B.A. (1970). Iodine metabolism and breast cancer.
Trans. NY. Acad. Sci., 32, 911.
HEDLEY, A.S., SPIEGELHALTER, D.J., JONES, S.J. & 4
others. (1981). Breast cancer and thyroid disease. Fact
or fallacy? Lancet, i, 131.
HEITZ, P., MOSER, H. & STAUB, J.J. (1976). Thyroid
cancer: A study of 573 thyroid tumors and 161
autopsy cases observed over a thirty-year period.
Cancer, 37, 2329.92 E. RON et al.
HEMBREE, W.C. & VANDE WIELE, R.L. (1978).
Hypothyroidism: Female reproductive system. In: The
Thyroid. (Eds. Werner & Ingbar), New York: Harper
& Row. p. 914.
HOFFMAN, D.A. & McCONAHEY, W.J. (1981). Thyroid
disease and breast cancer. Lancet, i, 730.
HUMPHREY, L.S. & SWERDLOW, M. (1964). The
relationship of breast disease to thyroid disease.
Cancer, 17, 1170.
ICD-O. (1976). International Classification of Diseases for
Oncology. Geneva: World Health Association.
KAPDI, C.G. & WOLFE, J.N. (1976). Breast cancer.
Relationship to thyroid supplements for
hypothyroidism. J.A.M.A., 236, 1124.
MACFARLANE, I.A., ROBINSON, E.L., BUSH, H. & 4 others.
(1980). Thyroid function in patients with benign and
malignant breast disease. Br. J. Cancer, 41, 478.
MEISSNER, W.A. (1978). Pathology of the thyroid. In: The
Thyroid. (Eds. Werner & Ingbar) New York: Harper &
Row. p. 444.
MITTRA, I. & HAYWARD, J.L. (1974). Hypothalmic-
Pituitary-Thyroid axis in breast cancer. Lancet, i, 885.
MONSON, R.R. (1974). Analysis of relative survival and
proportional mortality. Comput. Biomed. Res., 7, 325.
POCHIN, E.E. (1976). Alcohol and cancer of breast and
thyroid. Lancet, i, 1137.
REPERT, R.W. (1952). Breast carcinoma study: relation of
thyroid and diabetes. J. Mich. St. Med. Soc., 51, 1315.
ROSE, D.P. & DAVIS, T.E. (1978). Plasma thyroid
stimulating hormone and thyroxine concentrations in
breast cancer. Cancer, 41, 666.
ROTHMAN, K.J. & BOICE, J.D., Jr. (1979). Epidemiologic
Analysis with a Programmable Calculator. DHEW
Publ. No. (NIH) 79-1649. Washington, D.C.: U.S.
Govt. Print Off.
SCHOENBERG, B. (1977). Multiple Primary Malignant
Neoplasms. The Connecticut Experience, 1935-1964.
New York: Springer Verlag.
SCHOENBERG, B.S., FRAUMENI, J.F. Jr., GREENBERG,
R.A. & CHRISTINE, B. (1973). Multiple primary
malignancies in Connecticut, 1935-1964. Clues to
aetiology. In: Multiple Primary Malignant Twnours.
(Ed. Severi), Perugia: Division of Cancer Research.
SCHOTTENFELD, D. & BERG, J.W. (1971). Incidence of
multiple primary cancers. IV. Cancers of the female
breast and genital organs. J. Natl Cancer Inst., 46,
161.
SHANDS, W.C. & GATLING, R.R. (1970). Cancer of the
thyroid: Review of 109 cases. Ann. Surg., 171, 735.
SHAPIRO, S., SLONE, D., KAUFMAN, D.W. & 8 others.
(1980). Use of thyroid supplements in relation to the
risk of breast cancer. J.A.M.A., 244, 1685.
STADEL, B.V. (1976). Dietary iodine and risk of breast,
endometrial and ovarian cancer. Lancet, i, 890.
WATERHOUSE, J., MUIR, C., CORREA, P. & POWELL, J.
(1976). Cancer Incidence in Five Continents. Vol. III.
Lyon: IARC.
WILLIAMS, E.D. (1979). The aetiology of thyroid tumors.
Clin. Endocrinol. Metabol., 8, 193.
WILLIAMS, R.R. (1976). Breast and thyroid cancer and
malignant melanoma promoted by alcohol-induced
pituitary secretion of prolactin, T.S.H. and M.S.H.
Lancet, i, 996.